Clinical Trial

A Study of VRN101099 in Patients With HER2-Positive Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 28, 2025 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This FIH open-label study aims to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor effect of VRN101099 in patients with HER2-positive solid tumors for whom no standard therapies are available.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-30.
Status change: Not Yet Recruiting → Recruiting 2025-08-21
Trial Details
NCT Number NCT06806982
Lead Sponsor Voronoi, Inc
Conditions HER2-positive Solid Tumors
Enrollment 72 participants
Start Date 2025-02-17
Primary Completion 2026-05-01 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-28